Celera Genomics Group has taken a step toward life in the post-genomics space with its planned purchase of Axys Pharmaceuticals Inc., which will provide CRA with biology and chemistry capabilities needed to build a fully integrated drug discovery business system. And CRA is looking for more deals to move further downstream.

CRA has already started to develop its own vaccine and antibody-based therapeutics, but had no small molecule discovery capability before announcing the